FR2666657A1 - Methode pour determiner le risque d'evolution d'une infection provoquee par hiv et sa mise en óoeuvre. - Google Patents
Methode pour determiner le risque d'evolution d'une infection provoquee par hiv et sa mise en óoeuvre. Download PDFInfo
- Publication number
- FR2666657A1 FR2666657A1 FR9111118A FR9111118A FR2666657A1 FR 2666657 A1 FR2666657 A1 FR 2666657A1 FR 9111118 A FR9111118 A FR 9111118A FR 9111118 A FR9111118 A FR 9111118A FR 2666657 A1 FR2666657 A1 FR 2666657A1
- Authority
- FR
- France
- Prior art keywords
- dhea
- amount
- hiv
- sample
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 20
- 208000015181 infectious disease Diseases 0.000 title claims description 3
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims abstract description 60
- 230000028327 secretion Effects 0.000 claims abstract description 8
- 239000012530 fluid Substances 0.000 claims abstract description 7
- 210000002966 serum Anatomy 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 9
- 238000003018 immunoassay Methods 0.000 claims description 9
- 210000001124 body fluid Anatomy 0.000 claims description 7
- 239000010839 body fluid Substances 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 230000000984 immunochemical effect Effects 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims 1
- 238000004811 liquid chromatography Methods 0.000 claims 1
- 239000002689 soil Substances 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 abstract description 10
- 208000037357 HIV infectious disease Diseases 0.000 abstract description 7
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract description 7
- 150000003839 salts Chemical class 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 47
- 229960002847 prasterone Drugs 0.000 description 47
- 208000030507 AIDS Diseases 0.000 description 20
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 12
- 241000725303 Human immunodeficiency virus Species 0.000 description 11
- 102000003992 Peroxidases Human genes 0.000 description 7
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 7
- 108040007629 peroxidase activity proteins Proteins 0.000 description 7
- 229950009829 prasterone sulfate Drugs 0.000 description 7
- 229960000890 hydrocortisone Drugs 0.000 description 6
- 239000011324 bead Substances 0.000 description 5
- 238000005534 hematocrit Methods 0.000 description 5
- 230000000652 homosexual effect Effects 0.000 description 5
- 206010001513 AIDS related complex Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004970 cd4 cell Anatomy 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 108050001427 Avidin/streptavidin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108010027044 HIV Core Protein p24 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 210000003103 bodily secretion Anatomy 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005184 men's health Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000012205 qualitative assay Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- -1 rods Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012206 semi-quantitative assay Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE326690A IE63418B1 (en) | 1990-09-10 | 1990-09-10 | Progression risk of HIV by assay of dehydroepiandrosterone in body fluid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2666657A1 true FR2666657A1 (fr) | 1992-03-13 |
| FR2666657B1 FR2666657B1 (enrdf_load_stackoverflow) | 1997-02-21 |
Family
ID=11038235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9111118A Granted FR2666657A1 (fr) | 1990-09-10 | 1991-09-09 | Methode pour determiner le risque d'evolution d'une infection provoquee par hiv et sa mise en óoeuvre. |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JPH04351964A (enrdf_load_stackoverflow) |
| DE (1) | DE4129932A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2666657A1 (enrdf_load_stackoverflow) |
| GB (1) | GB2249833B (enrdf_load_stackoverflow) |
| IE (1) | IE63418B1 (enrdf_load_stackoverflow) |
| IT (1) | IT1255009B (enrdf_load_stackoverflow) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4230684A (en) * | 1978-03-16 | 1980-10-28 | Cornell Research Foundation, Inc. | Method for determining steroids in human body liquids |
| DE3812595A1 (de) * | 1987-04-16 | 1988-10-27 | Colthurst Ltd | Arzneimittel zur prophylaxe und therapie von retrovirus-infektionen |
| WO1990008959A1 (en) * | 1989-02-01 | 1990-08-09 | E.I. Du Pont De Nemours And Company | HIV p17 ASSAYS FOR MONITORING DEVELOPMENT OF AIDS |
| EP0383313A2 (en) * | 1989-02-15 | 1990-08-22 | Mochida Pharmaceutical Co., Ltd. | Reagent for immunoassay, and kit containing the same |
-
1990
- 1990-09-10 IE IE326690A patent/IE63418B1/en not_active IP Right Cessation
-
1991
- 1991-09-09 DE DE4129932A patent/DE4129932A1/de not_active Withdrawn
- 1991-09-09 IT ITMI912378A patent/IT1255009B/it active IP Right Grant
- 1991-09-09 JP JP3307281A patent/JPH04351964A/ja active Pending
- 1991-09-09 FR FR9111118A patent/FR2666657A1/fr active Granted
- 1991-09-09 GB GB9119256A patent/GB2249833B/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4230684A (en) * | 1978-03-16 | 1980-10-28 | Cornell Research Foundation, Inc. | Method for determining steroids in human body liquids |
| DE3812595A1 (de) * | 1987-04-16 | 1988-10-27 | Colthurst Ltd | Arzneimittel zur prophylaxe und therapie von retrovirus-infektionen |
| WO1990008959A1 (en) * | 1989-02-01 | 1990-08-09 | E.I. Du Pont De Nemours And Company | HIV p17 ASSAYS FOR MONITORING DEVELOPMENT OF AIDS |
| EP0383313A2 (en) * | 1989-02-15 | 1990-08-22 | Mochida Pharmaceutical Co., Ltd. | Reagent for immunoassay, and kit containing the same |
Non-Patent Citations (4)
| Title |
|---|
| KALIMI ET AL. 'The biologic role of dehydroepiandrosterone (DHEA)' 1990 , DE GRUYTER , BERLIN Merril et al.: 'Reduced plasma dehydroepiandrosterone concentrations in HIV infection and Alzheimer's disease' * |
| LA PRESSE MéDICALE vol. 30, 10 Septembre 1988, PARIS page 1540 BRICAIRE ET AL. 'Taux des hormones sexuelles et du cortisol chez les malades .....' * |
| THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM vol. 70, no. 3, Mars 1990, PHILADELPHIA, PA pages 572 - 577 VILLETTE ET AL. 'Circadian variations in plasma levels of hypophyseal, adrenocortical ........' * |
| THE JOURNAL OF INFECTIOUS DISEASES vol. 164, no. 5, Novembre 1991, CHICAGO, ILL. pages 864 - 868 JACOBSON ET AL. 'Decreased serum dehydroepiandosterone is associated with an increased progression .......' * |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH04351964A (ja) | 1992-12-07 |
| IE63418B1 (en) | 1995-04-19 |
| ITMI912378A0 (it) | 1991-09-09 |
| FR2666657B1 (enrdf_load_stackoverflow) | 1997-02-21 |
| IT1255009B (it) | 1995-10-11 |
| ITMI912378A1 (it) | 1993-03-09 |
| GB2249833A (en) | 1992-05-20 |
| DE4129932A1 (de) | 1992-03-12 |
| GB2249833B (en) | 1994-09-07 |
| GB9119256D0 (en) | 1991-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Smith et al. | C4d fixing, luminex binding antibodies—a new tool for prediction of graft failure after heart transplantation | |
| Rao et al. | An avidin-biotin microELISA for rapid measurement of total and allergen-specific human IgE | |
| EP0399024A1 (fr) | ANTICORPS MONOCLONAUX ANTI-INTERLEUKINES 1$g(a) ET 1$g(b), LEUR PROCEDE DE PRODUCTION ET APPLICATIONS DESDITS ANTICORPS A LA DETECTION DES INTERLEUKINES 1$g(a) et 1$g(b) ET EN THERAPEUTIQUE | |
| WO1993003381A1 (en) | Assay for free secretory component and methods for monitoring organ rejection | |
| EP0311492B1 (fr) | Trousse et méthode de dosage immunométrique applicables à des cellules entières | |
| CN117990906A (zh) | 凝血酶-抗凝血酶复合体的测定试剂及测定方法 | |
| Beutner et al. | Sensitivity and specificity of IgA-class antiendomysial antibodies for dermatitis herpetiformis and findings relevant to their pathogenic significance | |
| WO2002039123A1 (fr) | Trousse et procede de detection de la proteine esm-1 | |
| WO1992008983A1 (en) | Hiv marker/aids vaccine | |
| FI90801C (fi) | Menetelmä anti-HIV:n määrittämiseksi, tarvikkeet sitä varten ja niiden käyttö tässä menetelmässä | |
| EP0676052B1 (fr) | Detection de la mucoviscidose ou d'une mutation du gene cftr | |
| DK173838B1 (da) | Fremgangsmåde til påvisning af tilstedeværelsen af et blodpladecelleoverfladeantigen | |
| EP2274623B1 (fr) | Procede de diagnostic d'une hypertension arterielle pulmonaire | |
| FR2666657A1 (fr) | Methode pour determiner le risque d'evolution d'une infection provoquee par hiv et sa mise en óoeuvre. | |
| EP0801744B1 (fr) | Reactif peptidique permettant de detecter une infection primaire a virus d'epstein-barr par recherche des anticorps correspondants, et procede d'utilisation de ce reactif | |
| HUE030649T2 (en) | Procedure for Anticipating the Progress of HIV Disease | |
| CA2148268A1 (fr) | Methode d'immunodosage specifique de la glutathion peroxydase plasmatique humaine | |
| Knapp et al. | Serum lipoprotein (a) levels in elderly black and white men in the Charleston Heart Study | |
| JP3499875B2 (ja) | 解離性大動脈瘤を検出するための抗体試薬及びその用途 | |
| Vierucci et al. | New Anti‐Beta‐Lipoprotein Sera in Transfused Children with Thalassemia | |
| JP2004069672A (ja) | 酸化アポリポタンパク質ａｉ及びそれを含有する酸化リポタンパク質の測定法及びキット | |
| EP0920628B1 (fr) | NOUVELLE METHODE D'ANALYSE DES RECEPTEURS PLAQUETTAIRES GPIIb/IIIa | |
| FR2585837A1 (fr) | Procede pour determiner la presence de ige specifique dans des serums humains | |
| Drouet et al. | Quantification and molecular analysis of plasmatic HLA‐BCw molecules with a locus B and Cw HLA specific mAb (B1. 23.2 mAb) | |
| FR2495326A1 (fr) | Procede de dosage immunologique, du type a agglutination, pour deceler des anticorps de type immunoglobuline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TP | Transmission of property |